ABSTRACT
Wegener granulomatosis (WG), the most common of the pulmonary granulomatous vasculitides,
typically involves the upper respiratory tract, lower respiratory tract (bronchi and
lung), and kidney, with varying degrees of disseminated vasculitis. The term Granulomatosis with Polyangiitis (Wegener) was recently proposed to replace the older term, WG. The term granulomatosis with polyangiitis can be abbreviated to GPA , with the idea that the eponym Wegener would be omitted over time. Cardinal histologic features include a necrotizing vasculitis involving small vessels,
extensive “geographic” necrosis, and granulomatous inflammation. Clinical manifestations
of WG are protean; virtually any organ can be involved. The spectrum and severity
of the disease are heterogeneous, ranging from indolent disease involving only one
site to fulminant, multiorgan vasculitis. The pathogenesis of WG has not been elucidated,
but both cellular and humoral components are involved. Circulating antibodies against
cytoplasmic components of neutrophils [anti-neutrophil cytoplasmic antibodies (c-ANCAs)]
likely play a role in the pathogenesis, and often correlate with activity of the disease.
Treatment strategies are evolving. Cyclophosphamide (CYC) plus corticosteroids (CSs)
is the mainstay of therapy for generalized, multisystemic WG. Historically, the combination
of CYC plus CS was used for a minimum of 12 months, but concern about late toxicities
associated with CYC has led to novel treatment approaches. Currently, short-course
(3 to 6 months) induction treatment with CYC plus CS, followed by maintenance therapy
with less toxic agents (e.g., methotrexate, azathioprine) is recommended. Further,
methotrexate combined with CS may be adequate for limited, non-life-threatening WG.
Recent studies suggest that rituximab may be useful for induction therapy or CYC-refractory
WG. The role of other immunomodulatory agents (including trimethoprim-sulfamethoxazole)
is also explored.
KEYWORDS
Wegener granulomatosis - granulomatosis with polyangiitis - granulomatous vasculitis
- pulmonary vasculitis - capillaritis - anti-neutrophil cytoplasmic antibodies - geographic
necrosis
REFERENCES
1
Lynch III J P, White E, Tazelaar H, Langford C A.
Wegener's granulomatosis: evolving concepts in treatment.
Semin Respir Crit Care Med.
2004;
25
(5)
491-521
2
Hoffman G S, Kerr G S, Leavitt R Y et al..
Wegener granulomatosis: an analysis of 158 patients.
Ann Intern Med.
1992;
116
(6)
488-498
3
Reinhold-Keller E, Beuge N, Latza U et al..
An interdisciplinary approach to the care of patients with Wegener's granulomatosis:
long-term outcome in 155 patients.
Arthritis Rheum.
2000;
43
(5)
1021-1032
4
Langford C A, Hoffman G S.
Rare diseases.3: Wegener's granulomatosis.
Thorax.
1999;
54
(7)
629-637
5
Abdou N I, Kullman G J, Hoffman G S et al..
Wegener's granulomatosis: survey of 701 patients in North America: changes in outcome
in the 1990s.
J Rheumatol.
2002;
29
(2)
309-316
6
Falk R J, Gross W L, Guillevin L et al..
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.
Ann Rheum Dis.
2011;
70
(4)
704
7
Falk R J, Jennette J C.
ANCA disease: where is this field heading?.
J Am Soc Nephrol.
2010;
21
(5)
745-752
8
Woywodt A, Haubitz M, Haller H, Matteson E L.
Wegener's granulomatosis.
Lancet.
2006;
367
(9519)
1362-1366
9
Travis W D.
Pathology of pulmonary vasculitis.
Semin Respir Crit Care Med.
2004;
25
(5)
475-482
10
Travis W D, Hoffman G S, Leavitt R Y, Pass H I, Fauci A S.
Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung
biopsies from 67 patients.
Am J Surg Pathol.
1991;
15
(4)
315-333
11
Devaney K O, Travis W D, Hoffman G, Leavitt R, Lebovics R, Fauci A S.
Interpretation of head and neck biopsies in Wegener's granulomatosis: a pathologic
study of 126 biopsies in 70 patients.
Am J Surg Pathol.
1990;
14
(6)
555-564
12
Watts R A, Scott D G.
Epidemiology of the vasculitides.
Semin Respir Crit Care Med.
2004;
25
(5)
455-464
13
Koldingsnes W, Nossent H.
Epidemiology of Wegener's granulomatosis in northern Norway.
Arthritis Rheum.
2000;
43
(11)
2481-2487
14
Watts R A, Gonzales-Gay M, Garcia-Porrua C, Lane S E, Bentham G, Scott D G.
ANCA-associated vasculitis in two European regions.
Clin Exp Immunol.
2000;
120
(suppl 1)
60
15
Watts R A, Al-Taiar A, Scott D G, Macgregor A J.
Prevalence and incidence of Wegener's granulomatosis in the UK general practice research
database.
Arthritis Rheum.
2009;
61
(10)
1412-1416
16
Mahr A, Guillevin L, Poissonnet M, Aymé S.
Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis,
and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture
estimate.
Arthritis Rheum.
2004;
51
(1)
92-99
17
Cotch M F, Hoffman G S, Yerg D E, Kaufman G I, Targonski P, Kaslow R A.
The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence,
annual mortality, and geographic disease distribution from population-based data sources.
Arthritis Rheum.
1996;
39
(1)
87-92
18
Gibson A, Stamp L K, Chapman P T, O'Donnell J L.
The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern
Hemisphere region.
Rheumatology (Oxford).
2006;
45
(5)
624-628
19
Mohammad A J, Jacobsson L T, Mahr A D, Sturfelt G, Segelmark M.
Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa
and Churg-Strauss syndrome within a defined population in southern Sweden.
Rheumatology (Oxford).
2007;
46
(8)
1329-1337
20
Stegmayr B G, Gothefors L, Malmer B, Müller Wiefel D E, Nilsson K, Sundelin B.
Wegener granulomatosis in children and young adults: a case study of ten patients.
Pediatr Nephrol.
2000;
14
(3)
208-213
21
Belostotsky V M, Shah V, Dillon M J.
Clinical features in 17 paediatric patients with Wegener granulomatosis.
Pediatr Nephrol.
2002;
17
(9)
754-761
22
Rottem M, Fauci A S, Hallahan C W et al..
Wegener granulomatosis in children and adolescents: clinical presentation and outcome.
J Pediatr.
1993;
122
(1)
26-31
23
Grisaru S, Yuen G W, Miettunen P M, Hamiwka L A.
Incidence of Wegener's granulomatosis in children.
J Rheumatol.
2010;
37
(2)
440-442
24
Leavitt R Y, Fauci A S, Bloch D A et al..
The American College of Rheumatology 1990 criteria for the classification of Wegener's
granulomatosis.
Arthritis Rheum.
1990;
33
(8)
1101-1107
25
Jennette J C, Falk R J, Andrassy K et al..
Nomenclature of systemic vasculitides. Proposal of an international consensus conference.
Arthritis Rheum.
1994;
37
(2)
187-192
26
Kallenberg C G.
Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis.
Curr Opin Rheumatol.
2007;
19
(1)
17-24
27
Kallenberg C G.
Pathogenesis of PR3-ANCA associated vasculitis.
J Autoimmun.
2008;
30
(1-2)
29-36
28
Gubbels S P, Barkhuizen A, Hwang P H.
Head and neck manifestations of Wegener's granulomatosis.
Otolaryngol Clin North Am.
2003;
36
(4)
685-705
29
Cannady S B, Batra P S, Koening C et al..
Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases.
Laryngoscope.
2009;
119
(4)
757-761
30
Rasmussen N.
Management of the ear, nose, and throat manifestations of Wegener granulomatosis:
an otorhinolaryngologist's perspective.
Curr Opin Rheumatol.
2001;
13
(1)
3-11
31
Ah-See K W, McLaren K, Maran A G.
Wegener's granulomatosis presenting as major salivary gland enlargement.
J Laryngol Otol.
1996;
110
(7)
691-693
32
Gassling V, Wiltfang J, Hampe J, Bräsen J H, Both M, Moosig F.
Salivary gland swelling in Wegener's granulomatosis: a rare cause of a frequent symptom.
J Rheumatol.
2010;
37
(12)
2633-2635
33
Bucolo S, Torre V, Montemagno A, Beatrice F.
Wegener's granulomatosis presenting with otologic and neurologic symptoms: clinical
and pathological correlations.
J Oral Pathol Med.
2003;
32
(7)
438-440
34
Liu S Y, Vlantis A C, Lee W C.
Bilateral parotid and submandibular gland enlargement: rare features of Wegener's
granulomatosis.
J Laryngol Otol.
2003;
117
(2)
148-150
35
Lloyd G, Lund V J, Beale T, Howard D.
Rhinologic changes in Wegener's granulomatosis.
J Laryngol Otol.
2002;
116
(7)
565-569
36
Takwoingi Y M, Dempster J H.
Wegener's granulomatosis: an analysis of 33 patients seen over a 10-year period.
Clin Otolaryngol Allied Sci.
2003;
28
(3)
187-194
37
Newman N J, Slamovits T L, Friedland S, Wilson W B.
Neuro-ophthalmic manifestations of meningocerebral inflammation from the limited form
of Wegener's granulomatosis.
Am J Ophthalmol.
1995;
120
(5)
613-621
38
Haynes B F, Fishman M L, Fauci A S, Wolff S M.
The ocular manifestations of Wegener's granulomatosis: fifteen years experience and
review of the literature.
Am J Med.
1977;
63
(1)
131-141
39
Fauci A S, Haynes B F, Katz P, Wolff S M.
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85
patients for 21 years.
Ann Intern Med.
1983;
98
(1)
76-85
40
Woo T L, Francis I C, Wilcsek G A, Coroneo M T, McNab A A, Sullivan T J. Australasian
Orbital and Adnexal Wagener's Study Group .
Australasian orbital and adnexal Wegener's granulomatosis.
Ophthalmology.
2001;
108
(9)
1535-1543
41
Harper S L, Letko E, Samson C M et al..
Wegener's granulomatosis: the relationship between ocular and systemic disease.
J Rheumatol.
2001;
28
(5)
1025-1032
42
Tarabishy A, Schulte M, Papaliodis G N, Hoffman G S.
Wegener's granulomatosis: clinical manifestations, differential diagnosis, and management
of ocular and systemic disease.
Surv Ophthalmol.
2010;
55
193-214
43
Valmaggia C, Neuweiler J.
Orbital involvement as the first manifestation in classic Wegener's granulomatosis.
Orbit.
2001;
20
(3)
231-237
44
Lamprecht P, Reinhold-Keller E, Gross W L, Reuter M.
Clinical images: orbital granuloma and subglottic tracheal stenosis in Wegener's granulomatosis.
Arthritis Rheum.
2000;
43
(7)
1654
45
Niskopoulou M, Du Toit N.
Optic neuritis as a feature of Wegener's granulomatosis.
Eye (Lond).
2002;
16
(3)
320-321
46
Blum M, Andrassy K, Adler D, Hartmann M, Völcker H E.
Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis
with ocular involvement.
Graefes Arch Clin Exp Ophthalmol.
1997;
235
(9)
599-602
47
Wardyn K A, Ycińska K, Matuszkiewicz-Rowińska J, Chipczyńska M.
Pseudotumour orbitae as the initial manifestation in Wegener's granulomatosis in a
7-year-old girl.
Clin Rheumatol.
2003;
22
(6)
472-474
48
Hardwig P W, Bartley G B, Garrity J A.
Surgical management of nasolacrimal duct obstruction in patients with Wegener's granulomatosis.
Ophthalmology.
1992;
99
(1)
133-139
49
Pakrou N, Selva D, Leibovitch I.
Wegener's granulomatosis: ophthalmic manifestations and management.
Semin Arthritis Rheum.
2006;
35
(5)
284-292
50
Langford C A, Sneller M C, Hallahan C W et al..
Clinical features and therapeutic management of subglottic stenosis in patients with
Wegener's granulomatosis.
Arthritis Rheum.
1996;
39
(10)
1754-1760
51
Daum T E, Specks U, Colby T V et al..
Tracheobronchial involvement in Wegener's granulomatosis.
Am J Respir Crit Care Med.
1995;
151
(2 Pt 1)
522-526
52
Gluth M B, Shinners P A, Kasperbauer J L.
Subglottic stenosis associated with Wegener's granulomatosis.
Laryngoscope.
2003;
113
(8)
1304-1307
53
Screaton N J, Sivasothy P, Flower C D, Lockwood C M.
Tracheal involvement in Wegener's granulomatosis: evaluation using spiral CT.
Clin Radiol.
1998;
53
(11)
809-815
54 Lynch III J P, Quint L E. Tracheobronchial and esophageal manifestations of systemic
diseases. In: Cummings C E, ed. Otolaryngology Head and Neck Surgery. 3rd ed. St.
Louis: Mosby-Year Book; 1998: 2343-2367
55
Quint L E, Whyte R I, Kazerooni E A et al..
Stenosis of the central airways: evaluation by using helical CT with multiplanar reconstructions.
Radiology.
1995;
194
(3)
871-877
56
Nouraei S A, Obholzer R, Ind P W et al..
Results of endoscopic surgery and intralesional steroid therapy for airway compromise
due to tracheobronchial Wegener's granulomatosis.
Thorax.
2008;
63
(1)
49-52
57
Gotway M B, Golden J A, LaBerge J M et al..
Benign tracheobronchial stenoses: changes in short-term and long-term pulmonary function
testing after expandable metallic stent placement.
J Comput Assist Tomogr.
2002;
26
(4)
564-572
58
Schokkenbroek A A, Franssen C F, Dikkers F G.
Dilatation tracheoscopy for laryngeal and tracheal stenosis in patients with Wegener's
granulomatosis.
Eur Arch Otorhinolaryngol.
2008;
265
(5)
549-555
59
Hoffman G S, Thomas-Golbanov C K, Chan J, Akst L M, Eliachar I.
Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional
corticosteroids and dilation.
J Rheumatol.
2003;
30
(5)
1017-1021
60
Cordier J F, Valeyre D, Guillevin L, Loire R, Brechot J M.
Pulmonary Wegener's granulomatosis: a clinical and imaging study of 77 cases.
Chest.
1990;
97
(4)
906-912
61
Gómez-Puerta J A, Hernández-Rodríguez J, López-Soto A, Bosch X.
Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease.
Chest.
2009;
136
(4)
1101-1111
62
Shin M S, Young K R, Ho K J.
Wegener's granulomatosis upper respiratory tract and pulmonary radiographic manifestations
in 30 cases with pathogenetic consideration.
Clin Imaging.
1998;
22
(2)
99-104
63
Komócsi A, Reuter M, Heller M, Muraközi H, Gross W L, Schnabel A.
Active disease and residual damage in treated Wegener's granulomatosis: an observational
study using pulmonary high-resolution computed tomography.
Eur Radiol.
2003;
13
(1)
36-42
64 Lynch III J P, Leatherman J W. Alveolar hemorrhage syndromes. In: Fishman A E,
ed. Pulmonary Diseases and Disorders. 3rd ed. New York, NY: McGraw-Hill; 1997: 1193-1210
65
Travis W D, Colby T V, Lombard C, Carpenter H A.
A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy
confirmation.
Am J Surg Pathol.
1990;
14
(12)
1112-1125
66
Lee K S, Kim T S, Fujimoto K et al..
Thoracic manifestation of Wegener's granulomatosis: CT findings in 30 patients.
Eur Radiol.
2003;
13
(1)
43-51
67
Reuter M, Schnabel A, Wesner F et al..
Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings
and clinical scoring of disease activity.
Chest.
1998;
114
(2)
500-506
68
Sheehan R E, Flint J D, Müller N L.
Computed tomography features of the thoracic manifestations of Wegener granulomatosis.
J Thorac Imaging.
2003;
18
(1)
34-41
69
Michael C W, Flint A.
The cytologic features of Wegener's granulomatosis.
Am J Clin Pathol.
1998;
110
(1)
10-15
70
Carruthers D M, Connor S, Howie A J et al..
Percutaneous image-guided biopsy of lung nodules in the assessment of disease activity
in Wegener's granulomatosis.
Rheumatology (Oxford).
2000;
39
(7)
776-782
71
Uner A H, Rozum-Slota B, Katzenstein A L.
Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener's granulomatosis:
a clinicopathologic study of 16 cases.
Am J Surg Pathol.
1996;
20
(7)
794-801
72
Katzenstein A L, Locke W K.
Solitary lung lesions in Wegener's granulomatosis: pathologic findings and clinical
significance in 25 cases.
Am J Surg Pathol.
1995;
19
(5)
545-552
73
Yousem S.
Bronchocentric injury in Wegener's granulomatosis: a report of five cases.
Hum Pathol.
1991;
22
534-540
74
Casian A, Jayne D.
Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis,
Churg-Strauss syndrome and renal limited vasculitis.
Curr Opin Rheumatol.
2011;
23
(1)
12-17
75
Aasarød K, Bostad L, Hammerstrøm J, Jørstad S, Iversen B M.
Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis.
Nephrol Dial Transplant.
2001;
16
(5)
953-960
76
Bajema I M, Hagen E C, Hermans J et al..
Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis.
Kidney Int.
1999;
56
(5)
1751-1758
77
Mekhail T M, Hoffman G S.
Long-term outcome of Wegener's granulomatosis in patients with renal disease requiring
dialysis.
J Rheumatol.
2000;
27
(5)
1237-1240
78
Jayne D R, Gaskin G, Rasmussen N European Vasculitis Study Group et al.
Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive
therapy for severe renal vasculitis.
J Am Soc Nephrol.
2007;
18
(7)
2180-2188
79
Lionaki S, Falk R J.
Removing antibody and preserving glomeruli in ANCA small-vessel vasculitis.
J Am Soc Nephrol.
2007;
18
(7)
1987-1989
80
Szpirt W M, Heaf J G, Petersen J.
Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's
granulomatosis—a clinical randomized controlled trial.
Nephrol Dial Transplant.
2011;
26
206-213
81
Aasarød K, Iversen B M, Hammerstrøm J, Bostad L, Vatten L, Jørstad S.
Wegener's granulomatosis: clinical course in 108 patients with renal involvement.
Nephrol Dial Transplant.
2000;
15
(5)
611-618
82
Hensle T W, Mitchell M E, Crooks K K, Robinson D.
Urologic manifestations of Wegener granulomatosis.
Urology.
1978;
12
(5)
553-556
83
Huong D L, Papo T, Piette J C et al..
Urogenital manifestations of Wegener's granulomatosis.
Medicine (Baltimore).
1995;
74
(3)
152-161
84
Baker S B, Robinson D R.
Unusual renal manifestations of Wegener's granulomatosis: report of two cases.
Am J Med.
1978;
64
(5)
883-889
85
Frigui M, Ben Hmida M, Kechaou M, Jlidi R, Bahloul Z.
Wegener's granulomatosis presenting as multiple bilateral renal masses: case report
and literature review.
Rheumatol Int.
2009;
29
(6)
679-683
86
Gunnarsson R, Omdal R, Kjellevold K H, Ellingsen C L.
Wegener's granulomatosis of the prostate gland.
Rheumatol Int.
2004;
24
120-122
87
Nishino H, Rubino F A, DeRemee R A, Swanson J W, Parisi J E.
Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive
patients at the Mayo Clinic.
Ann Neurol.
1993;
33
(1)
4-9
88
de Groot K, Schmidt D K, Arlt A C, Gross W L, Reinhold-Keller E.
Standardized neurologic evaluations of 128 patients with Wegener granulomatosis.
Arch Neurol.
2001;
58
(8)
1215-1221
89
Holle J U, Gross W L.
Neurological involvement in Wegener's granulomatosis.
Curr Opin Rheumatol.
2011;
23
(1)
7-11
90
Weinberger L M, Cohen M L, Remler B F, Naheedy M H, Leigh R J.
Intracranial Wegener's granulomatosis.
Neurology.
1993;
43
(9)
1831-1834
91
Garovic V D, Clarke B L, Chilson T S, Specks U.
Diabetes insipidus and anterior pituitary insufficiency as presenting features of
Wegener's granulomatosis.
Am J Kidney Dis.
2001;
37
(1)
E5
92
Woywodt A, Knoblauch H, Kettritz R, Schneider W, Göbel U.
Sudden death and Wegener's granulomatosis of the pituitary.
Scand J Rheumatol.
2000;
29
(4)
264-266
93
Mattioli F, Capra R, Rovaris M et al..
Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated
small vessel vasculitides.
J Neurol Sci.
2002;
195
(2)
161-166
94
Murphy J M, Gomez-Anson B, Gillard J H et al..
Wegener granulomatosis: MR imaging findings in brain and meninges.
Radiology.
1999;
213
(3)
794-799
95
Mentzel H J, Neumann T, Fitzek C, Sauner D, Reichenbach J R, Kaiser W A.
MR imaging in Wegener granulomatosis of the spinal cord.
AJNR Am J Neuroradiol.
2003;
24
(1)
18-21
96
Comfere N I, Macaron N C, Gibson L E.
Cutaneous manifestations of Wegener's granulomatosis: a clinicopathologic study of
17 patients and correlation to antineutrophil cytoplasmic antibody status.
J Cutan Pathol.
2007;
34
(10)
739-747
97
Barksdale S K, Hallahan C W, Kerr G S, Fauci A S, Stern J B, Travis W D.
Cutaneous pathology in Wegener's granulomatosis: a clinicopathologic study of 75 biopsies
in 46 patients.
Am J Surg Pathol.
1995;
19
(2)
161-172
98
Morelli S, Gurgo Di Castelmenardo A M, Conti F et al..
Cardiac involvement in patients with Wegener's granulomatosis.
Rheumatol Int.
2000;
19
(6)
209-212
99
Kouba D J, Kirsch D G, Mimouni D, Nousari C H.
Wegener's granulomatosis with cardiac involvement masquerading as Lyme disease.
Clin Exp Rheumatol.
2003;
21
(5)
647-649
100
Parry S D, Clark D M, Campbell J.
Coronary arteritis in Wegener's granulomatosis causing fatal myocardial infarction.
Hosp Med.
2000;
61
(4)
284-285
101
Musuruana J L, Cavallasca J A, Berduc J, Vicario J.
Coronary artery aneurysms in Wegener's granulomatosis.
Joint Bone Spine.
2010;
Dec 29. [Epub ahead of print]
102
Schmidt W A, Seipelt E, Molsen H P, Poehls C, Gromnica-ihle E J.
Vasculitis of the internal carotid artery in Wegener's granulomatosis: comparison
of ultrasonography, angiography, and MRI.
Scand J Rheumatol.
2001;
30
(1)
48-50
103
Blockmans D, Baeyens H, Van Loon R, Lauwers G, Bobbaers H.
Periaortitis and aortic dissection due to Wegener's granulomatosis.
Clin Rheumatol.
2000;
19
(2)
161-164
104
Chang Y J, Kerr L D.
Isolated abdominal vasculitis as an atypical presentation of Wegener's granulomatosis.
Am J Gastroenterol.
2000;
95
(1)
297-298
105
Haworth S J, Pusey C D.
Severe intestinal involvement in Wegener's granulomatosis.
Gut.
1984;
25
(11)
1296-1300
106
Camilleri M, Pusey C D, Chadwick V S, Rees A J.
Gastrointestinal manifestations of systemic vasculitis.
Q J Med.
1983;
52
(206)
141-149
107
Steele C, Bohra S, Broe P, Murray F E.
Acute upper gastrointestinal haemorrhage and colitis: an unusual presentation of Wegener's
granulomatosis.
Eur J Gastroenterol Hepatol.
2001;
13
(8)
993-995
108
Qian Q, Cornell L, Chandan V, Hartman R, Caples S.
Hemorrhagic colitis as a presenting feature of Wegener granulomatosis.
J Gastrointestin Liver Dis.
2010;
19
(4)
445-447
109
Sokol R J, Farrell M K, McAdams A J.
An unusual presentation of Wegener's granulomatosis mimicking inflammatory bowel disease.
Gastroenterology.
1984;
87
(2)
426-432
110
Zen Y, Sunagozaka H, Tsuneyama K et al..
Incomplete septal cirrhosis associated with Wegener's granulomatosis.
Liver.
2002;
22
(5)
388-393
111
Holl-Ulrich K, Klass M.
Wegener s granulomatosis with granulomatous liver involvement.
Clin Exp Rheumatol.
2010;
28
(1, suppl 57)
88-89
112
Rentsch J, McColl G.
Splenic infarction in Wegener's granulomatosis.
J Rheumatol.
2000;
27
(6)
1554-1555
113
Kalaitzoglou I, Drevelengas A, Palladas P, Asimaki A.
MRI appearance of pulmonary Wegener's granulomatosis with concomitant splenic infarction.
Eur Radiol.
1998;
8
(3)
367-370
114
Boomsma M M, Stegeman C A, van der Leij M J et al..
Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil
cytoplasmic antibody levels: a prospective study.
Arthritis Rheum.
2000;
43
(9)
2025-2033
115
Gómez-Puerta J A, Bosch X.
Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update.
Am J Pathol.
2009;
175
(5)
1790-1798
116
Dijstelbloem H M, Scheepers R H, Oost W W et al..
Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease
relapse.
Arthritis Rheum.
1999;
42
(9)
1823-1827
117
Savige J A, Chang L, Cook L, Burdon J, Daskalakis M, Doery J.
Alpha 1-antitrypsin deficiency and anti-proteinase 3 antibodies in anti-neutrophil
cytoplasmic antibody (ANCA)-associated systemic vasculitis.
Clin Exp Immunol.
1995;
100
(2)
194-197
118
Borgmann S, Endisch G, Urban S, Sitter T, Fricke H.
A linkage disequilibrium between genes at the serine protease inhibitor gene cluster
on chromosome 14q32.1 is associated with Wegener's granulomatosis.
Clin Immunol.
2001;
98
(2)
244-248
119
Walton E W.
Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis).
BMJ.
1958;
2
(5091)
265-270
120
Hoffman G S.
“Wegener's granulomatosis”: the path traveled since 1931.
Medicine (Baltimore).
1994;
73
(6)
325-329
121
Hollander D, Manning R T.
The use of alkylating agents in the treatment of Wegener's granulomatosis.
Ann Intern Med.
1967;
67
(2)
393-398
122
Fauci A S, Wolff S M.
Wegener's granulomatosis: studies in eighteen patients and a review of the literature.
Medicine (Baltimore).
1973;
52
(6)
535-561
123
Reinhold-Keller E, Kekow J, Schnabel A et al..
Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on
the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis.
Arthritis Rheum.
1994;
37
(6)
919-924
124
Guillevin L, Cordier J F, Lhote F et al..
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide
versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's
granulomatosis.
Arthritis Rheum.
1997;
40
(12)
2187-2198
125
Pagnoux C, Hogan S L, Chin H et al..
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated
small-vessel vasculitis: comparison of two independent cohorts.
Arthritis Rheum.
2008;
58
(9)
2908-2918
126
Talar-Williams C, Hijazi Y M, Walther M M et al..
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.
Ann Intern Med.
1996;
124
(5)
477-484
127
Charlier C, Henegar C, Launay O et al..
Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients.
Ann Rheum Dis.
2009;
68
(5)
658-663
128
Faurschou M, Sorensen I J, Mellemkjaer L et al..
Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide
therapy in a cohort of 293 patients.
J Rheumatol.
2008;
35
(1)
100-105
129
Jayne D, Rasmussen N, Andrassy K European Vasculitis Study Group et al.
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil
cytoplasmic autoantibodies.
N Engl J Med.
2003;
349
(1)
36-44
130
Reinhold-Keller E, Fink C O, Herlyn K, Gross W L, De Groot K.
High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance
of remission with low-dose methotrexate.
Arthritis Rheum.
2002;
47
(3)
326-332
131
Pagnoux C, Mahr A, Hamidou M A French Vasculitis Study Group et al.
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
N Engl J Med.
2008;
359
(26)
2790-2803
132
Hiemstra T F, Walsh M, Mahr A European Vasculitis Study Group (EUVAS) et al.
Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil
cytoplasmic antibody-associated vasculitis: a randomized controlled trial.
JAMA.
2010;
304
(21)
2381-2388
133
Stone J H. Wegener's Granulomatosis Etanercept Trial Research Group .
Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's
granulomatosis etanercept trial.
Arthritis Rheum.
2003;
48
(8)
2299-2309
134
Exley A R, Bacon P A, Luqmani R A, Kitas G D, Carruthers D M, Moots R.
Examination of disease severity in systemic vasculitis from the novel perspective
of damage using the vasculitis damage index (VDI).
Br J Rheumatol.
1998;
37
(1)
57-63
135
Stone J H, Hoffman G S, Merkel P A International Network for the Study of the Systemic
Vasculitides (INSSYS) et al.
A disease-specific activity index for Wegener's granulomatosis: modification of the
Birmingham Vasculitis Activity Score.
Arthritis Rheum.
2001;
44
(4)
912-920
136
Hoffman G S, Leavitt R Y, Fleisher T A, Minor J R, Fauci A S.
Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide.
Am J Med.
1990;
89
(4)
403-410
137
de Groot K, Harper L, Jayne D R EUVAS (European Vasculitis Study Group) et al.
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil
cytoplasmic antibody-associated vasculitis: a randomized trial.
Ann Intern Med.
2009;
150
(10)
670-680
138
Seror R, Pagnoux C, Ruivard M et al..
Treatment strategies and outcome of induction-refractory Wegener's granulomatosis
or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory
disease in the WEGENT trial.
Ann Rheum Dis.
2010;
69
2125-2130
139
Jayne D.
Leflunomide versus methotrexate in Wegener's granulomatosis.
Rheumatology (Oxford).
2007;
46
(7)
1047-1048
140
Langford C A.
Wegener's granulomatosis: current and upcoming therapies.
Arthritis Res Ther.
2003;
5
(4)
180-191
141
Langford C A, Talar-Williams C, Sneller M C.
Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis.
Long-term renal outcome in patients with glomerulonephritis.
Arthritis Rheum.
2000;
43
(8)
1836-1840
142
De Groot K, Rasmussen N, Bacon P A et al..
Randomized trial of cyclophosphamide versus methotrexate for induction of remission
in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis Rheum.
2005;
52
(8)
2461-2469
143
Langford C A, Talar-Williams C, Sneller M C.
Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis.
Arthritis Rheum.
2004;
51
(2)
278-283
144
Jones R B, Tervaert J W, Hauser T European Vasculitis Study Group et al.
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
N Engl J Med.
2010;
363
(3)
211-220
145
Stone J H, Merkel P A, Spiera R RAVE-ITN Research Group et al.
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
N Engl J Med.
2010;
363
(3)
221-232
146
Stegeman C A, Tervaert J W, de Jong P E, Kallenberg C G. Dutch Co-Trimoxazole Wegener
Study Group .
Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's
granulomatosis.
N Engl J Med.
1996;
335
(1)
16-20
147
Reinhold-Keller E, De Groot K, Rudert H, Nölle B, Heller M, Gross W L.
Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the
phase of disease.
QJM.
1996;
89
(1)
15-23
148
Klemmer P J, Chalermskulrat W, Reif M S, Hogan S L, Henke D C, Falk R J.
Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel
vasculitis.
Am J Kidney Dis.
2003;
42
(6)
1149-1153
149
Wang C C, Shiang J C, Tsai M K et al..
Prompt plasmapheresis successfully rescue pulmonary-renal syndrome caused by ANCA-negative
microscopic polyangiitis.
Clin Rheumatol.
2009;
28
(12)
1457-1460
150
Marder W, McCune W J.
Advances in immunosuppressive therapy.
Semin Respir Crit Care Med.
2007;
28
(4)
398-417
151
Haubitz M, Koch K M, Brunkhorst R.
Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated
vasculitis.
Nephrol Dial Transplant.
1998;
13
(8)
2074-2076
152
Lynch III J P, McCune W J.
Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders.
Am J Respir Crit Care Med.
1997;
155
(2)
395-420
153
Langford C A, Talar-Williams C, Barron K S, Sneller M C.
A staged approach to the treatment of Wegener's granulomatosis: induction of remission
with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission
maintenance.
Arthritis Rheum.
1999;
42
(12)
2666-2673
154
Stone J H, Holbrook J T, Marriott M A Wegener's Granulomatosis Etanercept Trial Research
Group et al.
Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
Arthritis Rheum.
2006;
54
(5)
1608-1618
155
Bernatsky S, Ramsey-Goldman R, Clarke A E.
Malignancies and cyclophosphamide exposure in Wegener's granulomatosis.
J Rheumatol.
2008;
35
(1)
11-13
156
Mahr A, Girard T, Agher R, Guillevin L.
Analysis of factors predictive of survival based on 49 patients with systemic Wegener's
granulomatosis and prospective follow-up.
Rheumatology (Oxford).
2001;
40
(5)
492-498
157
de Groot K, Adu D, Savage C O. EUVAS (European vasculitis study group) .
The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and
critical review.
Nephrol Dial Transplant.
2001;
16
(10)
2018-2027
158
Sneller M C, Hoffman G S, Talar-Williams C, Kerr G S, Hallahan C W, Fauci A S.
An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate
and prednisone.
Arthritis Rheum.
1995;
38
(5)
608-613
159
Langford C A, Sneller M C, Hoffman G S.
Methotrexate use in systemic vasculitis.
Rheum Dis Clin North Am.
1997;
23
(4)
841-853
160
de Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross W L.
Induction of remission in Wegener's granulomatosis with low dose methotrexate.
J Rheumatol.
1998;
25
(3)
492-495
161
Villa-Forte A, Clark T M, Gomes M et al..
Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year
single-practice experience.
Medicine (Baltimore).
2007;
86
(5)
269-277
162
de Groot K, Reinhold-Keller E, Tatsis E et al..
Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's
granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole.
Arthritis Rheum.
1996;
39
(12)
2052-2061
163
Stone J H, Tun W, Hellman D B.
Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily
prednisone as the initial therapy of choice.
J Rheumatol.
1999;
26
(5)
1134-1139
164
Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude F J.
Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic
polyangiitis: a pilot study in 11 patients with renal involvement.
J Am Soc Nephrol.
1999;
10
(9)
1965-1971
165
Iatrou C, Zerbala S, Revela I et al..
Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal
involvement.
Clin Nephrol.
2009;
72
(1)
31-37
166
Joy M S, Hogan S L, Jennette J C, Falk R J, Nachman P H.
A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel
vasculitis.
Nephrol Dial Transplant.
2005;
20
(12)
2725-2732
167
Metzler C, Fink C, Lamprecht P, Gross W L, Reinhold-Keller E.
Maintenance of remission with leflunomide in Wegener's granulomatosis.
Rheumatology (Oxford).
2004;
43
(3)
315-320
168
Metzler C, Miehle N, Manger K German Network of Rheumatic Diseases et al.
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of
remission in Wegener's granulomatosis.
Rheumatology (Oxford).
2007;
46
(7)
1087-1091
169
Henes J C, Kanz L, Koetter I.
Rituximab and leflunomide for Wegener's granulomatosis: a long-term follow-up.
Rheumatol Int.
2011;
31
425-426
170
Bremer J P, Ullrich S, Laudien M, Gross W L, Lamprecht P.
Methotrexate plus leflunomide for the treatment of relapsing Wegener's granulomatosis:
a retrospective uncontrolled study.
Clin Exp Rheumatol.
2010;
28
(1, suppl 57)
67-71
171
Israel H L, Patchefsky A S, Saldana M J.
Wegener's granulomatosis, lymphomatoid granulomatosis, and benign lymphocytic angiitis
and granulomatosis of lung: recognition and treatment.
Ann Intern Med.
1977;
87
(6)
691-699
172
Weiner S R, Paulus H E.
Treatment of Wegener's granulomatosis.
Semin Respir Med.
1989;
10
156-161
173
DeRemee R A.
The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion
or vision?.
Arthritis Rheum.
1988;
31
(8)
1068-1074
174
Georgi J, Ulmer M, Gross W L.
Cotrimoxazole in Wegener's granulomatosis—a prospective study [in German].
Immun Infekt.
1991;
19
(3)
97-98
175
Hoffman G S.
Immunosuppressive therapy is always required for the treatment of limited Wegener's
granulomatosis.
Sarcoidosis Vasc Diffuse Lung Dis.
1996;
13
(3)
249-252
176
Stegeman C A, Tervaert J W, Sluiter W J, Manson W L, de Jong P E, Kallenberg C G.
Association of chronic nasal carriage of Staphylococcus aureus and higher relapse
rates in Wegener granulomatosis.
Ann Intern Med.
1994;
120
(1)
12-17
177
Falagas M E, Manta K G, Betsi G I, Pappas G.
Infection-related morbidity and mortality in patients with connective tissue diseases:
a systematic review.
Clin Rheumatol.
2007;
26
(5)
663-670
178
White E S, Lynch J P.
Pharmacological therapy for Wegener's granulomatosis.
Drugs.
2006;
66
(9)
1209-1228
179
Mukhtyar C, Luqmani R.
Current state of tumour necrosis factor alpha blockade in Wegener's granulomatosis.
Ann Rheum Dis.
2005;
64
(suppl 4)
iv31-iv36
180
Specks U, Fervenza F C, McDonald T J, Hogan M C.
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
Arthritis Rheum.
2001;
44
(12)
2836-2840
181
Jayne D R, Chapel H, Adu D et al..
Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent
disease activity.
QJM.
2000;
93
(7)
433-439
182
Dick A D, Meyer P, James T et al..
Campath-1H therapy in refractory ocular inflammatory disease.
Br J Ophthalmol.
2000;
84
(1)
107-109
183
Walsh M, Chaudhry A, Jayne D.
Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated
vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
Ann Rheum Dis.
2008;
67
(9)
1322-1327
184
Lockwood C M.
New treatment strategies for systemic vasculitis: the role of intravenous immune globulin
therapy.
Clin Exp Immunol.
1996;
104
(suppl 1)
77-82
185
Lockwood C M, Thiru S, Stewart S et al..
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.
QJM.
1996;
89
(12)
903-912
186
Jayne D R, Rasmussen N.
Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis:
initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.
Mayo Clin Proc.
1997;
72
(8)
737-747
187
Kool J, de Keizer R J, Siegert C E.
Antithymocyte globulin treatment of orbital Wegener granulomatosis: a follow-up study.
Am J Ophthalmol.
1999;
127
(6)
738-739
188
Schmitt W H, Birck R, Heinzel P A et al..
Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin:
an open study in seven patients.
Nephrol Dial Transplant.
2005;
20
(6)
1083-1092
189
Birck R, Warnatz K, Lorenz H M et al..
15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis:
a six-month open-label trial to evaluate safety and efficacy.
J Am Soc Nephrol.
2003;
14
(2)
440-447
190
Flossmann O, Baslund B, Bruchfeld A et al..
Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.
Ann Rheum Dis.
2009;
68
(7)
1125-1130
191
Papo T, Le Thi Huong D, Wiederkehr J L et al..
Etoposide in Wegener's granulomatosis.
Rheumatology (Oxford).
1999;
38
(5)
473-475
192
Stone J H, Uhlfelder M L, Hellmann D B, Crook S, Bedocs N M, Hoffman G S.
Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month
open-label trial to evaluate safety.
Arthritis Rheum.
2001;
44
(5)
1149-1154
193
Clarke A E, Bitton A, Eappen R, Danoff D S, Esdaile J M.
Treatment of Wegener's granulomatosis after renal transplantation: is cyclosporine
the preferred treatment?.
Transplantation.
1990;
50
(6)
1047-1051
194
Allen N B, Caldwell D S, Rice J R, McCallum R M.
Cyclosporin A therapy for Wegener's granulomatosis.
Adv Exp Med Biol.
1993;
336
473-476
195
Ghez D, Westeel P F, Henry I, Pruna A, Fournier A, Lassoued K.
Control of a relapse and induction of long-term remission of Wegener's granulomatosis
by cyclosporine.
Am J Kidney Dis.
2002;
40
(2)
E6
196
Koening C L, Hernández-Rodríguez J, Molloy E S, Clark T M, Hoffman G S.
Limited utility of rapamycin in severe, refractory Wegener's granulomatosis.
J Rheumatol.
2009;
36
(1)
116-119
197
Statkute L, Oyama Y, Barr W G et al..
Autologous non-myeloablative hematopoietic stem cell transplantation for refractory
systemic vasculitis.
Ann Rheum Dis.
2008;
67
991-997
198
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group .
Etanercept plus standard therapy for Wegener's granulomatosis.
N Engl J Med.
2005;
352
(4)
351-361
199
Josselin L, Mahr A, Cohen P et al..
Infliximab efficacy and safety against refractory systemic necrotising vasculitides:
long-term follow-up of 15 patients.
Ann Rheum Dis.
2008;
67
(9)
1343-1346
200
Bartolucci P, Ramanoelina J, Cohen P et al..
Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides:
an open pilot study on 10 patients.
Rheumatology (Oxford).
2002;
41
(10)
1126-1132
201
Booth A D, Jefferson H J, Ayliffe W, Andrews P A, Jayne D R.
Safety and efficacy of TNFalpha blockade in relapsing vasculitis.
Ann Rheum Dis.
2002;
61
(6)
559
202
Booth A, Harper L, Hammad T et al..
Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic
antibody-associated systemic vasculitis.
J Am Soc Nephrol.
2004;
15
(3)
717-721
203
Lamprecht P, Voswinkel J, Lilienthal T et al..
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.
Rheumatology (Oxford).
2002;
41
(11)
1303-1307
204
Hermann J, Reittner P, Scarpatetti M, Graninger W.
Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab.
Ann Rheum Dis.
2006;
65
(5)
691-692
205
Seror R, Mahr A, Ramanoelina J, Pagnoux C, Cohen P, Guillevin L.
Central nervous system involvement in Wegener granulomatosis.
Medicine (Baltimore).
2006;
85
(1)
54-65
206
Cheung C M, Murray P I, Savage C O.
Successful treatment of Wegener's granulomatosis associated scleritis with rituximab.
Br J Ophthalmol.
2005;
89
(11)
1542
207
Ramos-Casals M, Brito-Zerón P, Muñoz S et al..
Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
Medicine (Baltimore).
2007;
86
(4)
242-251
208
Hinze C H, Colbert R A.
B-cell depletion in Wegener's granulomatosis.
Clin Rev Allergy Immunol.
2008;
34
372-379
209
Stasi R, Stipa E, Del Poeta G, Amadori S, Newland A C, Provan D.
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated
vasculitis treated with rituximab.
Rheumatology (Oxford).
2006;
45
(11)
1432-1436
210
Aries P M, Hellmich B, Voswinkel J et al..
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous
manifestations.
Ann Rheum Dis.
2006;
65
(7)
853-858
211
Keogh K A, Wylam M E, Stone J H, Specks U.
Induction of remission by B lymphocyte depletion in eleven patients with refractory
antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis Rheum.
2005;
52
(1)
262-268
212
Memet B, Rudinskaya A, Krebs T, Oelberg D.
Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease
in response to rituximab.
J Clin Rheumatol.
2005;
11
(6)
314-318
213
Tamura N, Matsudaira R, Hirashima M et al..
Two cases of refractory Wegener's granulomatosis successfully treated with rituximab.
Intern Med.
2007;
46
(7)
409-414
214
Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G.
Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but
temporary response.
Scand J Rheumatol.
2005;
34
(3)
229-232
215
Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L.
Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing
Wegener's granulomatosis: a study on 8 patients.
Clin Exp Rheumatol.
2007;
25
(1, suppl 44)
S23-S27
216
Hermle T, Goestemeyer A K, Sweny P, Burns A.
Successful therapeutic use of rituximab in refractory Wegener's granulomatosis after
renal transplantation.
Clin Nephrol.
2007;
68
(5)
322-326
217
Roccatello D, Baldovino S, Alpa M et al..
Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated
idiopathic systemic vasculitis with or without overt renal involvement.
Clin Exp Rheumatol.
2008;
26
(3, suppl 49)
S67-S71
218
Jones R B, Ferraro A J, Chaudhry A N et al..
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic
antibody-associated vasculitis.
Arthritis Rheum.
2009;
60
(7)
2156-2168
219
Sharma A, Kumar S, Wanchu A et al..
Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis
with rituximab.
Clin Rheumatol.
2010;
29
(1)
107-110
220
Martinez Del Pero M, Chaudhry A, Jones R B, Sivasothy P, Jani P, Jayne D.
B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis:
a cohort study.
Clin Otolaryngol.
2009;
34
(4)
328-335
221
Taylor S R, Salama A D, Joshi L, Pusey C D, Lightman S L.
Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.
Arthritis Rheum.
2009;
60
(5)
1540-1547
222
Onal S, Kazokoglu H, Koc A, Yavuz S.
Rituximab for remission induction in a patient with relapsing necrotizing scleritis
associated with limited Wegener's granulomatosis.
Ocul Immunol Inflamm.
2008;
16
(5)
230-232
223
Falk R J, Jennette J C.
Rituximab in ANCA-associated disease.
N Engl J Med.
2010;
363
(3)
285-286
224
Major E O.
Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.
Annu Rev Med.
2010;
61
35-47
225
Ramos-Casals M, Soto M J, Cuadrado M J, Khamashta M A.
Rituximab in systemic lupus erythematosus: a systematic review of off-label use in
188 cases.
Lupus.
2009;
18
(9)
767-776
226
Kazatchkine M D, Kaveri S V.
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.
N Engl J Med.
2001;
345
(10)
747-755
227
Ito-Ihara T, Ono T, Nogaki F et al..
Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated
rapidly progressive glomerulonephritis.
Nephron Clin Pract.
2006;
102
(1)
c35-c42
228
Martinez V, Cohen P, Pagnoux C French Vasculitis Study Group et al.
Intravenous immunoglobulins for relapses of systemic vasculitides associated with
antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective,
open-label study of twenty-two patients.
Arthritis Rheum.
2008;
58
(1)
308-317
229
Schmitt W H, Hagen E C, Neumann I, Nowack R, Flores-Suárez L F, van der Woude F J.
European Vasculitis Study Group .
Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG):
an open study in 15 patients.
Kidney Int.
2004;
65
(4)
1440-1448
230
Flossmann O, Jayne D R.
Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin.
Rheumatology (Oxford).
2010;
49
(3)
556-562
231
Imai H, Hotta O, Yoshimura M et al..
Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with
crescent formation: an open-label trial to evaluate safety and efficacy.
Clin Exp Nephrol.
2006;
10
(1)
40-54
232
Birck R, Newman M, Braun C et al..
15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival
and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis.
Nephrol Dial Transplant.
2006;
21
(1)
58-63
233
Krafcik S S, Covin R B, Lynch III J P, Sitrin R G.
Wegener's granulomatosis in the elderly.
Chest.
1996;
109
(2)
430-437
234
Koldingsnes W, Nossent J C.
Baseline features and initial treatment as predictors of remission and relapse in
Wegener's granulomatosis.
J Rheumatol.
2003;
30
(1)
80-88
235
Orens J B, Sitrin R G, Lynch III J P.
The approach to nonresolving pneumonia.
Med Clin North Am.
1994;
78
(5)
1143-1172
236 Lynch III J P, Raghu G. Major disease syndromes of unknown etiology. In: Baum G,
Crapo J, eds. Textbook of Pulmonary Disease. 6th ed. Boston, MA: Little, Brown; 1998:
431-476
237
Lynch III J P, Matteson E, McCune J W.
Wegener's granulomatosis: evolving concepts.
Medical Rounds.
1989;
2
67-80
Joseph P LynchIII M.D.
Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, The
David Geffen School of Medicine at UCLA
10833 Le Conte Ave., Rm. 37-131 CHS, Los Angeles, CA 90095-1690
Email: jplynch@mednet.ucla.edu